Condensed Consolidated Statement of Equity (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	Total		Silcon [Member]	Cytochroma [Member]	PROLOR [Member]	Farmadiet [Member]	Common Stock [Member]	Common Stock [Member] Silcon [Member]	Common Stock [Member] Cytochroma [Member]	Common Stock [Member] PROLOR [Member]	Common Stock [Member] Farmadiet [Member]	Treasury	Additional Paid-In Capital	Additional Paid-In Capital Silcon [Member]	Additional Paid-In Capital Cytochroma [Member]	Additional Paid-In Capital PROLOR [Member]	Additional Paid-In Capital Farmadiet [Member]	Acumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Noncontrolling Interests	Series D Preferred Stock	Series D Preferred Stock Common Stock [Member]	Series D Preferred Stock Additional Paid-In Capital	Notes [Member]	Notes [Member] Common Stock [Member]	Notes [Member] Additional Paid-In Capital
Beginning balance (audited) at Dec. 31, 2012	$ 178,894	[1]					$ 3,056					$ (7,457)	$ 565,201					$ 7,356	$ (388,770)	$ (492)
Beginning balance (audited), shares at Dec. 31, 2012							305,560,763					2,293,056
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	7,411												7,411
Exercise of Common Stock options	4,435						36						4,399
Exercise of Common Stock options, shares							3,604,783
Exercise of Common Stock warrants	626						12						614
Exercise of Common Stock warrants, shares							1,213,679
Series D Preferred Stock dividend													(3,015)								(3,015)
Conversion of Series D Preferred Stock																					24,386	113	24,273	20,839	24	20,815
Conversion of Series D Preferred Stock, shares																						11,290,320			2,396,145
Issuance of Common Stock in connection with acquisition			436	146,902	586,643			1	205	637				435	146,697	586,006
Stock Issued During Period, Share, Deferred Payment											585,703
Stock Issued During Period, Value, Deferred Payment						4,404					5						4,399
Issuance of Common Stock in connection with acquisition, shares								64,684	20,517,030	63,670,805
Net loss attributable to common shareholders before preferred stock dividend	(97,607)																		(97,607)
Net loss attributable to noncontrolling interests	(2,309)																			(2,309)
Other comprehensive loss	(4,119)																	(4,119)
Ending balance (unaudited) at Sep. 30, 2013	$ 867,926	[1]					$ 4,089					$ (7,457)	$ 1,357,235					$ 3,237	$ (486,377)	$ (2,801)
Ending balance (audited), shares at Sep. 30, 2013							408,903,912					2,293,056

[1] As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.